Nothing Special   »   [go: up one dir, main page]

PE20110671A1 - Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina - Google Patents

Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina

Info

Publication number
PE20110671A1
PE20110671A1 PE2011000136A PE2011000136A PE20110671A1 PE 20110671 A1 PE20110671 A1 PE 20110671A1 PE 2011000136 A PE2011000136 A PE 2011000136A PE 2011000136 A PE2011000136 A PE 2011000136A PE 20110671 A1 PE20110671 A1 PE 20110671A1
Authority
PE
Peru
Prior art keywords
activity
diazabicicloalkanes
modulators
derivatives
nicotine receptors
Prior art date
Application number
PE2011000136A
Other languages
English (en)
Inventor
V Srinivasa Murthy
Regina Whitaker
Scott R Breining
Matt S Melvin
Anatoly A Mazurov
Lan Miao
Yun-De Xiao
Philips S Hammond
Craig H Miller
Srinivisa Rao Akireddy
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PE20110671A1 publication Critical patent/PE20110671A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE n ES 0-1; Cy ES UN GRUPO HETEROARILO ELEGIDO DEL GRUPO DE 2-FURANILO, 3-FURANILO, 2-OXAZOLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(FURAN-2-ILCARBONIL)-3,7-DIAZABICILO[3.3.0]OCTANO; N-(4-FENILFURAN-2-ILCARBONIL)-3,7-DIAZABICICLO[3.3.0]OCTANO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN LA ACTIVIDAD DE LOS RECEPTORES NICOTINICOS NEURONALES DE ACETILCOLINA, UTILES EN EL TRATAMIENTO DE CONDICIONES Y TRASTORNOS, INCLUYENDO AQUELLOS ASOCIADOS CON LA DIFUNCION DEL SISTEMA NERVIOSO CENTRAL
PE2011000136A 2006-11-02 2007-10-31 Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina PE20110671A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02

Publications (1)

Publication Number Publication Date
PE20110671A1 true PE20110671A1 (es) 2011-10-20

Family

ID=39233054

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001487A PE20081441A1 (es) 2006-11-02 2007-10-31 Subtipo de amidas selectivas de diazabicicloalcanos
PE2011000136A PE20110671A1 (es) 2006-11-02 2007-10-31 Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007001487A PE20081441A1 (es) 2006-11-02 2007-10-31 Subtipo de amidas selectivas de diazabicicloalcanos

Country Status (33)

Country Link
US (6) US8114889B2 (es)
EP (2) EP2094703B1 (es)
JP (2) JP5539723B2 (es)
KR (2) KR101415705B1 (es)
CN (4) CN101528745B (es)
AR (2) AR063451A1 (es)
AT (2) ATE509022T1 (es)
AU (2) AU2007317433B2 (es)
BR (2) BRPI0722387A2 (es)
CA (1) CA2663925C (es)
CL (1) CL2007003155A1 (es)
CO (1) CO6180435A2 (es)
CY (1) CY1112374T1 (es)
DK (1) DK2094703T3 (es)
ES (2) ES2395212T3 (es)
HK (2) HK1149751A1 (es)
HR (1) HRP20110570T1 (es)
IL (2) IL197618A (es)
MX (1) MX2009004801A (es)
MY (2) MY156730A (es)
NO (1) NO20091251L (es)
NZ (2) NZ587847A (es)
PE (2) PE20081441A1 (es)
PL (1) PL2094703T3 (es)
PT (1) PT2094703E (es)
RS (1) RS51834B (es)
RU (2) RU2517693C2 (es)
SA (1) SA07280584B1 (es)
SI (1) SI2094703T1 (es)
TW (3) TWI405763B (es)
UA (2) UA106718C2 (es)
UY (1) UY30686A1 (es)
WO (1) WO2008057938A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
KR20100122508A (ko) * 2008-03-05 2010-11-22 타가셉트 인코포레이티드 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
CN102143963A (zh) * 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
AU2010243613B2 (en) 2009-04-30 2015-05-07 Glaxo Group Limited Oxazole substituted indazoles as PI3-kinase inhibitors
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
JP5536227B2 (ja) 2009-11-18 2014-07-02 スヴェン・ライフ・サイエンシズ・リミテッド α４β２ニコチン性アセチルコリン受容体リガンドとしての二環式化合物
AU2010337837B2 (en) 2009-12-29 2013-09-05 Suven Life Sciences Limited Alpha4beta2 neuronal nicotinic acetylcholine receptor ligands
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
HUE036117T2 (hu) 2013-11-26 2018-06-28 Hoffmann La Roche Oktahidro-ciklobuta[1,2-C;3,4-C']dipirrol származékok, mint autotaxin inhibitorok
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
PL3848028T3 (pl) * 2014-10-20 2024-11-18 Oyster Point Pharma, Inc. Sposoby leczenia stanów dotyczących oczu
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
BR112018006080A2 (pt) * 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
ES2893126T3 (es) 2016-04-07 2022-02-08 Oyster Point Pharma Inc Métodos de tratamiento de afecciones oculares
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
EP3483164B1 (en) 2017-03-20 2020-03-04 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
US12122778B2 (en) 2018-09-19 2024-10-22 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
CA3151612A1 (en) 2019-09-19 2021-03-25 George P. Luke Pyruvate kinase r (pkr) activating compositions
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
US5854239A (en) * 1993-12-29 1998-12-29 Pfizer Inc. Diazabicyclic neuokinin antagonists
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
JP2003516988A (ja) * 1999-12-14 2003-05-20 ニューロサーチ、アクティーゼルスカブ 新規ヘテロアリール−ジアザビシクロアルカン類
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
EP1368354A1 (en) 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
DE60215172T2 (de) 2001-07-06 2007-08-30 Neurosearch A/S Neue verbindungen, deren herstellung und verwendung
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
NZ540998A (en) * 2003-02-27 2008-06-30 Neurosearch As Novel diazabicyclic aryl derivatives
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
PL1761542T3 (pl) * 2004-06-09 2008-06-30 Hoffmann La Roche Pochodne oktahydropirolo[3,4-c]pirolu i ich zastosowanie jako środków przeciwwirusowych
CN101065385A (zh) 2004-07-22 2007-10-31 坎布里制药公司 治疗微生物感染的利福霉素衍生物
ES2434467T3 (es) * 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
BRPI0722387A2 (pt) 2023-02-23
JP2010509230A (ja) 2010-03-25
AU2010219323A1 (en) 2010-09-30
CN102020646B (zh) 2013-11-13
AU2007317433B2 (en) 2012-05-10
CO6180435A2 (es) 2010-07-19
ES2395212T3 (es) 2013-02-11
TW201114424A (en) 2011-05-01
NO20091251L (no) 2009-05-28
KR20100124356A (ko) 2010-11-26
TWI454262B (zh) 2014-10-01
EP2094703A1 (en) 2009-09-02
US8114889B2 (en) 2012-02-14
CA2663925C (en) 2015-04-21
RU2448969C2 (ru) 2012-04-27
TW201305176A (zh) 2013-02-01
UA98944C2 (ru) 2012-07-10
RU2517693C2 (ru) 2014-05-27
CN102942569A (zh) 2013-02-27
HK1149751A1 (en) 2011-10-14
UY30686A1 (es) 2009-08-03
UA106718C2 (uk) 2014-10-10
EP2094703B1 (en) 2011-05-11
CA2663925A1 (en) 2008-05-15
PT2094703E (pt) 2011-07-22
US8268860B2 (en) 2012-09-18
US20150080576A1 (en) 2015-03-19
EP2284171A1 (en) 2011-02-16
US20160039833A1 (en) 2016-02-11
AR063451A1 (es) 2009-01-28
US8859609B2 (en) 2014-10-14
CN101528745B (zh) 2011-09-14
AR079840A2 (es) 2012-02-22
NZ575557A (en) 2011-01-28
WO2008057938A1 (en) 2008-05-15
PL2094703T3 (pl) 2011-10-31
US20100081683A1 (en) 2010-04-01
AU2007317433A1 (en) 2008-05-15
SA07280584B1 (ar) 2010-11-02
RU2009138600A (ru) 2011-04-27
JP5739398B2 (ja) 2015-06-24
US8921410B2 (en) 2014-12-30
ES2395157T3 (es) 2013-02-08
MY145602A (en) 2012-03-15
KR20090074051A (ko) 2009-07-03
IL197618A0 (en) 2009-12-24
IL209026A (en) 2014-03-31
CY1112374T1 (el) 2015-12-09
IL197618A (en) 2013-09-30
TWI405763B (zh) 2013-08-21
US20120289572A1 (en) 2012-11-15
JP2013056919A (ja) 2013-03-28
KR101415705B1 (ko) 2014-07-04
US9580434B2 (en) 2017-02-28
MY156730A (en) 2016-03-15
NZ587847A (en) 2011-09-30
CN102838605A (zh) 2012-12-26
CN102020646A (zh) 2011-04-20
RU2009120674A (ru) 2010-12-10
HRP20110570T1 (hr) 2011-09-30
RS51834B (en) 2012-02-29
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
DK2094703T3 (da) 2011-08-29
CN102942569B (zh) 2015-10-28
TW200826935A (en) 2008-07-01
MX2009004801A (es) 2009-07-31
CL2007003155A1 (es) 2008-05-16
US20130005789A1 (en) 2013-01-03
JP5539723B2 (ja) 2014-07-02
PE20081441A1 (es) 2008-10-30
CN102838605B (zh) 2017-04-26
BRPI0717930A2 (pt) 2011-05-10
TWI404532B (zh) 2013-08-11
HK1133260A1 (en) 2010-03-19
ATE545646T1 (de) 2012-03-15
EP2284171B1 (en) 2012-02-15
SI2094703T1 (sl) 2011-07-29
ATE509022T1 (de) 2011-05-15
IL209026A0 (en) 2011-01-31
US20100173932A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
NO20080475L (no) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
PE20090363A1 (es) Moduladores de la gamma secretasa
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
MA50065A (fr) Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53
NO20060871L (no) Azepinderivater som farmasoytiske midler
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
UY28150A1 (es) Agentes terapeuticos
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
IL189927A0 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7&#39;-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
PE20061295A1 (es) Derivados de acetileno
EA200702253A1 (ru) Фармацевтическая композиция
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA31855B1 (fr) Carboxamides de n-phényl-bipyrrolidine substitués et leur utilisation thérapeutique
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
EA200970404A1 (ru) Соединения, проявляющие активность в отношении св

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed